IP Library › Granted Patent US 9,439,918
Granted Patent B2
US 9,439,918 · App. 14/309,178 · Granted Sep 13, 2016

Methods for treating gastrointestinal diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,439,918
App. No.
14/309,178
Granted
Sep 13, 2016
Kind
B2
Abstract

Described herein are macrolide and ketolide antibiotics and pharmaceutical compositions, methods, and uses thereof for treating gastrointestinal diseases.

Claims (30)

1. A method for treating a gastrointestinal disease caused by a bacteria in a host animal, the method comprising the step of administering an effective amount to the host animal of a compound of the formula

or a salt thereof, wherein:

R 10 is hydrogen or acyl;

W is H or F;

A is CH 2 ;

B is C 0 -C 10 alkyl; and

C is optionally substituted aryl or optionally substituted heteroaryl.

2. The method of claim 1 wherein R 10 is hydrogen.

3. The method of claim 1 wherein W is F.

4. The method of claim 1 wherein B is C 2 -C 4 alkyl.

5. The method of claim 1 wherein B is C 3 alkyl.

6. The method of claim 1 wherein C is optionally substituted aryl.

7. The method of claim 1 wherein C is amino-substituted aryl.

8. The method of claim 1 wherein C is optionally substituted phenyl.

9. The method of claim 1 wherein C is amino-substituted phenyl.

10. The method of claim 1 wherein C is 3-aminophenyl.

11. The method of claim 1 wherein the compound is CEM-101 or a salt thereof.

12. The method of claim 1 wherein the compound is CEM-101.

13. The method of claim 11 wherein the gastrointestinal disease is chronic gastritis.

14. The method of claim 11 wherein the gastrointestinal disease is diarrhea.

15. The method of claim 11 wherein the gastrointestinal disease is shigellosis.

16. The method of claim 11 wherein the gastrointestinal disease is caused at least in part by a bacteria selected from the group consisting of Salmonella, Shigella, Staphylococcus, Campylobacter, Helicobacter, Clostridium, Enterococcus, Escherichia coli, Listeria, and Yersinia.

17. The method of claim 11 wherein the gastrointestinal disease is caused at least in part by Enterococcus faecalis.

18. The method of claim 11 wherein the gastrointestinal disease is caused at least in part by Yersinia enterocolitica.

19. The method of claim 11 wherein the gastrointestinal disease is caused at least in part by Listeria monocytogenes.

20. The method of claim 11 wherein the gastrointestinal disease is caused at least in part by Helicobacter pylori and the disease is chronic gastritis.

21. The method of claim 11 wherein gastrointestinal disease is caused at least in part by Campylobacter and the disease is diarrhea.

22. The method of claim 11 wherein the gastrointestinal disease is caused at least in part by Salmonella and the disease is diarrhea.

23. The method of claim 11 wherein the bacteria is resistant to azithromycin.

24. The method of claim 11 wherein the bacteria is resistant to clarithromycin.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2019
From: CEMPRA PHARMACEUTICALS, INC.
To: TETARD, INC.
Reel/Frame 050056/0731 →
RELEASE OF SECURITY INTEREST Recorded Jun 4, 2019
From: CORTLAND CAPITAL MARKET SERVICES LLC
To: CEMPRA PHARMACEUTICALS, INC.
Reel/Frame 049363/0706 →
SECURITY INTEREST Recorded Jan 8, 2018
From: MELINTA THERAPEUTICS, INC.; REMPEX PHARMACEUTICALS, INC.; CEMPRA PHARMACEUTICALS, INC.; CEM-102 PHARMACEUTICALS, INC.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 045019/0552 →